Regeneron Pharmaceuticals Director Files Form 144 to Sell 400 Shares
REGENERON PHARMACEUTICALS, INC.
Subscribe to track REGN
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Form 144 Notice of Proposed Sale of Securities Issuer: REGENERON PHARMACEUTICALS, INC. ($REGN) Insider: Kathryn Guarini (Director) Shares to Sell: 400 Common Shares Estimated Value: $340,000.00 (~$850.00/share) Trading Plan: Rule 10b5-1 adopted on 02/13/2026 Broker: UBS Financial Services, Inc.
Comprehensive Analysis
Executive Summary
On September 2, 2026, Kathryn Guarini, a Director at REGENERON PHARMACEUTICALS, INC. ($REGN), filed a Form 144 proposing the sale of 400 shares of common stock with an aggregate market value of approximately $340,000.00 (implied price of $850.00 per share).
Transaction Details
- Security: Common Stock
- Amount: 400 shares
- Aggregate Market Value: $340,000.00
- Source of Shares: Stock option exercise (cash payment to issuer on 09/02/2026)
- Execution Broker: UBS Financial Services, Inc.
- Trading Plan: Executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026.
Prior Transactions (Past 3 Months)
- Sale Date: August 10, 2026
- Shares Sold: 400 shares
- Gross Proceeds: $320,000.00
Trading Significance Assessment
- Significance Level: Low
- Rationale: The proposed sale of 400 shares represents a negligible fraction (<0.001%) of the company's 101,137,842 outstanding shares. The transaction is conducted under a pre-scheduled Rule 10b5-1 trading plan, following a similar-sized option exercise and sale in August 2026, reflecting routine portfolio management.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.